ISSN: 1044-579X

Journal Home

Journal Guideline

Seminars in Cancer Biology Q1 Unclaimed

Academic Press Inc. United States

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Seminars in Cancer Biology is a journal indexed in SJR in Cancer Research with an H index of 169. It has a price of 2840 €. It has an SJR impact factor of 3,115 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 3,115.

Seminars in Cancer Biology focuses its scope in these topics and keywords: role, cancer, nuclear, induced, impact, inflammation, lymphomagenesisa, malignancy, mechanismsthe, microrna, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -

Categories: Cancer Research (Q1)

Price

2840 €

Inmediate OA

NPD

Embargoed OA

0 €

Non OA

Metrics

3,115

SJR Impact factor

169

H Index

384

Total Docs (Last Year)

465

Total Docs (3 years)

70432

Total Refs

6476

Total Cites (3 years)

439

Citable Docs (3 years)

13.3

Cites/Doc (2 years)

183.42

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Molecular Cancer Q1
JAMA oncology Q1
Signal Transduction and Targeted Therapy Q1
Journal of Hematology and Oncology Q1
Journal of the National Cancer Institute Q1

Compare this journals

Aims and Scope

Best articles by citations

Epstein-Barr virus and gastric carcinoma

Definition of tumor antigens suitable for vaccine construction

Translating mesothelioma molecular genomics and dependencies into precision oncology-based therapies

Chemokines in neuroectodermal development and their potential implication in cancer stem cell-driven metastasis

A broad-spectrum integrative design for cancer prevention and therapy: The challenge ahead

Chemokines in neuroectodermal tumour progression and metastasis

Genomic stability and tumorigenesis

Oncogenes and tumor angiogenesis

Oncogenes as therapeutic targets

Interactions between adenovirus proteins and the p53 pathway: the development of ONYX-015

Oncogenic growth factor receptors: implications for signal transduction therapy

Current criteria to establish human carcinogens

SHOW MORE ARTICLES

Putative role of 67 kDa elastin-laminin receptor in tumor invasion

Fusion oncogenes and tumor type specificity - insights from salivary gland tumors

Minimal residual disease (MRD) in follicular lymphoma in the era of immunotherapy with rituximab

Familial nasopharyngeal carcinoma

Regulating the regulators or how to elicit an immune response

Epigenetic and proteolytic inactivation of 14-3-3s in breast and prostate cancers

Hepatitis C virus and its pathogenesis

AGEs, RAGEs and s-RAGE; friend or foe for cancer

Introduction and overview

Where is the biology of CLL leading us?

Implication of direct host-tumor intercellular interactions in non-immune host resistance to neoplastic growth

Cyclin E as a prognostic and predictive marker in breast cancer